Exploration of α1-antitrypsin treatment protocol for islet transplantation: dosing plan and route of administration.
Life-long weekly infusions of human α1-antitrypsin (hAAT) are currently administered as augmentation therapy for patients with genetic AAT deficiency (AATD). Several recent clinical trials attempt to extend hAAT therapy to conditions outside AATD, including type 1 diabetes. Since the endpoint for AATD is primarily the reduction of risk for pulmonary emphysema, the present study explores hAAT dose protocols and routes of administration in attempt to optimize hAAT therapy for islet-related injury. Islet-grafted mice were treated with hAAT (Glassia™; i.p. or s.c.) under an array of clinically relevant dosing plans. Serum hAAT and immunocyte cell membrane association were examined, as well as parameters of islet survival. Results indicate that dividing the commonly prescribed 60 mg/kg i.p. dose to three 20 mg/kg injections is superior in affording islet graft survival; in addition, a short dynamic descending dose protocol (240→120→60→60 mg/kg i.p.) is comparable in outcomes to indefinite 60 mg/kg injections. While hAAT pharmacokinetics after i.p. administration in mice resembles exogenous hAAT treatment in humans, s.c. administration better imitated the physiological progressive rise of hAAT during acute phase responses; nonetheless, only the 60 mg/kg dose depicted an advantage using the s.c. route. Taken together, this study provides a platform for extrapolating an islet-relevant clinical protocol from animal models that use hAAT to protect islets. In addition, the study places emphasis on outcome-oriented analyses of drug efficacy, particularly important when considering that hAAT is presently at an era of drug-repurposing towards an extended list of clinical indications outside genetic AATD.
Ben-Gurion University of the Negev.
Boris M
BM
Baranovski
Ben-Gurion University of the Negev.
Eyal
E
Ozeri
Ben-Gurion University of the Negev.
Galit
G
Shahaf
Ben-Gurion University of the Negev.
David E
DE
Ochayon
Ben-Gurion University of the Negev.
Ronen
R
Schuster
Ben-Gurion University of the Negev.
Nofar
N
Bahar
Ben-Gurion University of the Negev.
Noa
N
Kalay
Ben-Gurion University of the Negev.
Pablo
P
Cal
Ben-Gurion University of the Negev.
Mark I
MI
Mizrahi
Ben-Gurion University of the Negev.
Omer
O
Nisim
Kamada, LTD.
Pnina
P
Strauss
Kamada, LTD.
Eran
E
Schenker
Ben-Gurion University of the Negev; lewis@bgu.ac.il.
Eli C
EC
Lewis
diabetes; inflammation